Waldencast plc has announced the launch of the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program through its subsidiary, Obagi Medical. The initiative will support the introduction of Obagi® saypha® MagIQ™, the company’s first FDA-approved injectable hyaluronic acid (HA) filler. The ALOHA program is designed as a structured clinical collaboration to collect real-world, practice-focused evidence by integrating the new filler into routine treatments and gathering standardized feedback from participating injectors and practice owners. The program aims to become the largest real-world evaluation of a newly launched HA injectable. Results from the program will be collected and are expected to inform post-launch education and scientific content; however, results have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waldencast plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9629313-en) on January 21, 2026, and is solely responsible for the information contained therein.